ArticleAMB Express2025
Akkermansia muciniphila alleviates metabolic disorders through gut microbiota-mediated tryptophan regulation.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Article
- Gut microbiota-derived tryptophan metabolites in cardiovascular disease: mechanisms, biomarkers, and precision interventions.Frontiers in microbiology · 2026Review
- Shengjiang San modification promotes colonic mucosal repair in ulcerative colitis rats by inhibiting lauric acid-Shigella synergistic damage via PKC signaling pathway.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-fat diet (HFD) consumption poses a significant public health threat due to its strong association with obesity, hyperlipidemia, cardiovascular diseases, and metabolic syndrome. While Akkermansia muciniphila has emerged as a promising probiotic for ameliorating metabolic disorders, the underlying mechanisms-specifically its interplay with intestinal tryptophan metabolism-remain poorly understood. Here, we demonstrate that A. muciniphila supplementation mitigates HFD-induced metabolic dysfunction in zebrafish by orchestrating a gut microbiota-tryptophan metabolite-AhR signaling axis. Firstly, A. muciniphila treatment effectively reduced the final weight of zebrafish, partially mitigated weight gain caused by HFD, and improved survival rate. In addition, A. muciniphila treatment reduced zebrafish adiposity, hepatic steatosis, and endotoxemia while enhancing the antioxidant capacity of the liver. We further found that A. muciniphila exerted anti-apoptotic effects, improved chronic low-grade inflammatory responses, enhanced antioxidant capacity, and repaired intestinal barriers induced by HFD. These effects were partially abolished by antibiotic pretreatment, confirming microbiota dependency. Subsequent 16S rRNA sequencing analysis revealed that A. muciniphila supplementation reshaped gut microbiota, enriching Staphylococcus and Vibrionaceae, while depleting Acinetobacter, Perlucidica, and Massilia. In addition to reducing lipid synthesis, metabolomic profiled the substantial changes in microbiota-regulated tryptophan metabolism, including increased levels of indole-3-lactic acid, indole-3-acetaldehyde, and 5-hydroxyindole acetic acid in Amuc group. These metabolites activated aryl hydrocarbon receptor (AhR), upregulating downstream IL-22 and improving intestinal integrity and chronic inflammatory response. Pathway analysis and enzyme gene expression detection indicated that A. muciniphila may inhibit the KP pathway while promoting the microbiota-dependent tryptophan metabolic pathway. This study establishes a novel link by which A. muciniphila exerts protective effects against HFD-induced metabolic syndrome through microbiota-mediated enhancement of tryptophan metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.